Methods: West Nile virus-infected Vero cells and influenza A H1N1-infected MDCK 23
cells were treated with omeprazole and/ or ribavirin. Herpes simplex virus 1 (HSV-1)-24 or HSV-2-infected Vero or HaCat cells were treated with omeprazole and/ or acyclovir. 25 Antiviral effects were determined by examination of cytopathogenic effects (CPE), 26 immune staining, and virus yield assay. Cell viability was investigated by MTT assay. 27
Results: Omeprazole concentrations up to 80µg/mL did not affect the antiviral effects 28 of ribavirin. In contrast, omeprazole increased the acyclovir-mediated effects on HSV-29 1-and HSV-2-induced CPE formation in a dose-dependent manner in Vero and HaCat 30 cells. Addition of omeprazole 80µg/mL resulted in a 10.8-fold reduction of the acyclovir 31 concentration that reduces CPE formation by 50% (IC50) in HSV-1-infected Vero cells 32 and in a 47.7-fold acyclovir IC50 reduction in HSV-1-infected HaCat cells. In HSV-2-33 infected cells, omeprazole reduced the acyclovir IC50 by 7.3-fold (Vero cells) or by 12.9-34 fold (HaCat cells). Omeprazole also enhanced the acyclovir-mediated effects on viral 35 antigen expression and virus replication in HSV-1-and HSV-2-infected cells. In HSV-36 1-infected HaCat cells, omeprazole 80µg/mL reduced the virus titre in the presence of 37 acyclovir 1µg/mL by 1.6x10 5 -fold. In HSV-2-infected HaCat cells omeprazole 80µg/mL 38 reduced the virus titre in the presence of acyclovir 2µg/mL by 9.2x10 3 -fold. The 39 investigated drug concentrations did not affect cell viability, neither alone nor in 40 combination.
Introduction 46
Omeprazole and other proton pump inhibitors were found to increase the activity of 47 anti-cancer drugs including the nucleoside analogue 5-fluorouracil (Luciani et al., 2004; 48 Ikemura et al., 2017) . Proton pump inhibitors are the most frequently prescribed drugs 49 for the treatment and prophylaxis of gastroesophageal reflux as well as of gastric and 50 duodenal ulcers that are associated with hyper-acidic states. Since they are known to 51 be well-tolerated, they were suggested as repositioning candidates for the use as part 52 of anti-cancer therapies (Ikemura et al., 2017) . 53
Here, we investigated the effects of omeprazole on the efficacy of the antiviral 54 nucleoside analogues acyclovir and ribavirin. We found that omeprazole enhanced the 55 antiviral effects of acyclovir against herpes simplex virus type 1 (HSV-1) and HSV-2 56 but did not influence the activity of ribavirin against West-Nile viruses or influenza 57 viruses. 
Cytopathogenic effect (CPE) reduction assay 85
For the investigation of HSV-1-and HSV-2-induced cytopathogenic effects (CPEs), 86 confluent Vero or HaCaT cell monolayer in 96-well microtiter plates were inoculated 87 with HSV-1 or HSV-2 at MOI 1 or 0.1, respectively. Following a 1h incubation period, 88 the inoculum was removed and the drugs, either alone or in combination, were added. 89
The virus-induced CPE was recorded microscopically after 48h post infection. 90
For the investigation of WNV-induced CPEs, Vero cell monolayers were infected with 91 MOI 0.1. Following a 1h virus incubation period, the medium was removed and infected 92 cells were incubated in medium containing different concentrations of drugs at the 93 respective concentration. The CPE was recorded at 48h post infection. 94
Confluent MDCK cell monolayers were infected with Influenza H1N1 (MOI 0.01). 95
Following a 1h virus incubation period, the medium was removed and infected cells 96 were incubated in medium containing different concentrations of drugs at the 97 respective concentration. The CPE was recorded at 24h post infection. 98
CPEs were scored by two independent examiners and expressed in % of the untreated 99 virus control that was defined to be 100%. 100
101
Immunostaining 102
Intracellular HSV protein was evaluated by immunostaining. Cells were fixed with 103 60/40 ice cold methanol/acetone for 15 min. Staining was performed using a rabbit 104 polyclonal antibody directed against HSV-1 (ab9533) and a sheep polyclonal antibody 105 directed against HSV-2 (ab21112) in combination with biotin-conjugated secondary 106 goat anti-rabbit (ab6720) and rabbit anti-sheep (ab6746) antibodies (all antibodies 107 derived from Abcam, Cambridge, UK). Protein was visualised using streptavidin-108 peroxidase complex with AEC as a substrate. 109
Viability assay 111
The cellular viability was assessed on confluent cell layers with the 3-(4,5-dimethyl-2-112 thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay method as described 113 previously (Michaelis et al., 2007) . The viability was expressed as percentage of non-114 treated control. 115 116 Results 117
Effects of omeprazole in combination with ribavirin on cytopathogenic effect 118 (CPE) formation in WNV-or influenza A H1N1-infected cells 119
Omeprazole 80µg/mL did not affect the effects of ribavirin on CPE formation in WNV-120 infected Vero cells or H1N1-infected MDCK cells ( Figure 1A , Suppl. Table 1) . 121 122
Effects of omeprazole in combination with acyclovir on HSV-1 and HSV-2 123
replication 124
In the presence of omeprazole 80µg/mL, acyclovir concentrations that reduced CPE 125 formation by 50% (IC50) were reduced by 11-fold in HSV-1-infected Vero cells and by The mechanism by which omeprazole enhances the activity of acyclovir seems to differ 154 from the mechanism by which the compound increases 5-fluorouracil efficacy. 155
Omeprazole pre-treatment was necessary to increase 5-fluorouracil activity (Luciani et 156 al., 2004) . In contrast, the combination of omeprazole and acyclovir exerted its 157 combined activity when added at the same time. 158
There is a need for improved therapies for HSV-1-and HSV-2-associated disease. 159
After primary infection, HSV-1 and HSV-2 establish life-long persistence which may 160 result in recurrent disease which typically manifests as herpes labialis or herpes 161 genitalis and which may be associated with significant morbidity (Gnann & Whitley, 162 2016; Heslop et al., 2016; Klysik et al., 2018) . Even in the case of herpes labialis, which is not commonly associated with complications, treatment success is not always 164 satisfactory as indicated by the introduction of topical acyclovir/ hydrocortisone 165 combinations (Nguyen et al., 2014) . In immunodeficient individuals, HSV-1/-2 infection 166 is often associated with more severe disease, and resistance formation to acyclovir is 167 a severe problem (Piret & Boivin, 2016; Karrasch et al., 2018) . Moreover, ocular HSV 168 infection is a major cause of blindness in industrialised countries (Klysik et al., 2018) . 169
In conclusion, omeprazole substantially enhances the antiviral effects of acyclovir in 170 HSV-1-and HSV-2-infected cells. Improved therapies for HSV-1/2 infection are highly 171 desirable, in particular for immunocompromised individuals. Since omeprazole is a 172 clinically well-established drug with a preferable safety profile, it is an excellent 173 candidate for drug repositioning strategies (Ikemura et al., 2017) . Virus titre (TCID 50 /mL) 10 0 10 1 10 2 10 4 10 5 10 6 10 7 10 9 10 3 10 8 OME20 OME20+ACV OME40 OME40+ACV OME40 OME40+ACV 10 0 10 1 10 2 10 4 10 5 10 6 10 7 10 3 10 8 N.D.
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